Clinical trials in patients with NHL are now ongoing with anti-CD22 antibody drug conjugates or unconjugated (DiJoseph et al. 2004, 2005; Leonard et al. 2004). The gene discussed is CD22; the disease is non-Hodgkin lymphoma.